Pharma medica - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,167,375 | 5,154,375 | 6,097,581 | 6,338,216 | 4,690,820 | 4,406,176 | 2,615,623 | 1,956,655 |
| Profit before tax | 158,583 | 583,102 | 1,000,400 | 1,240,448 | 1,271,639 | 1,199,918 | 152,521 | -192,679 |
| Net profit | 134,169 | 494,097 | 848,768 | 1,049,246 | 1,079,765 | 1,019,818 | 113,285 | -192,679 |
| Equity | 175,178 | 575,157 | 906,926 | 1,637,843 | 2,507,237 | 3,436,605 | 3,549,890 | 3,148,181 |
| Liabilities | 76,921 | 114,544 | 149,199 | 189,023 | 158,004 | 432,987 | 364,158 | 220,407 |
| Non-current assets | 0 | 743 | 3,227 | 148,302 | 666,215 | 693,682 | 1,076,037 | 1,138,097 |
| Current assets | 251,579 | 688,816 | 1,052,503 | 1,677,705 | 1,998,119 | 3,175,872 | 2,837,214 | 2,230,176 |
| Total assets | 251,579 | 689,559 | 1,055,730 | 1,826,007 | 2,664,334 | 3,869,554 | 3,913,251 | 3,368,273 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 4,581 | - |
| Social insurance contributions | - | - | - | - | - | 3,214 | - | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | +87.4% | +62.7% | +18.3% | +3.9% | -26.0% | -6.1% | -40.6% | -25.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 53.3% | 71.7% | 80.4% | 57.5% | 40.5% | 26.4% | 2.9% | -5.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 76.6% | 85.9% | 93.6% | 64.1% | 43.1% | 29.7% | 3.2% | -6.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.2% | 9.6% | 13.9% | 16.6% | 23.0% | 23.1% | 4.3% | -9.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.0% | 11.3% | 16.4% | 19.6% | 27.1% | 27.2% | 5.8% | -9.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,055,792 | 1,472,679 | 1,626,022 | 2,112,739 | 1,340,234 | 1,036,747 | 871,874 | 652,218 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharma medica - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-07-16 | 2024-07-23 | 545.05 |
| 2024-06-18 | 2024-06-18 | 548.66 |
| 2024-05-16 | 2024-05-20 | 547.46 |
| 2024-04-16 | 2024-04-16 | 540.36 |
| 2024-02-19 | 2024-02-19 | 501.46 |
| 2024-01-23 | 2024-02-14 | 501.46 |
| 2024-01-16 | 2024-01-22 | 501.01 |
| 2023-05-02 | 2023-05-03 | 310.78 |
| 2023-04-26 | 2023-04-28 | 310.78 |
| 2023-04-18 | 2023-04-25 | 307.04 |
| 2023-03-20 | 2023-03-26 | 315.80 |
| 2023-03-16 | 2023-03-19 | 941.69 |
| 2023-02-17 | 2023-02-28 | 260.04 |
| 2023-01-17 | 2023-01-26 | 119.81 |
| 2022-09-16 | 2022-09-18 | 25.17 |
| 2022-04-19 | 2022-04-20 | 334.85 |
Pharma medica - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-19 | 2024-12-21 | 3.85 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharma medica, UAB (code 304422863) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.96M, down 25.2% year on year and 55.6% below the 2023 level. Profitability weakened materially: net profit fell from €1.02M in 2023 to €113.3K in 2024, then turned into a net loss of €192.7K in 2025, with a profit margin of -9.8%. The latest two-year trend shows a clear revenue decline alongside a shift from solid profitability to loss. At year-end 2025, total assets stood at €3.37M, equity at €3.15M and liabilities at €220.4K, indicating a strong equity base and low leverage. The equity ratio was 93.5% and debt-to-equity 0.07. Return on equity was -6.1% and return on assets -5.7% in 2025. Asset turnover was 0.58x. Revenue per employee was €652.2K, while profit per employee was -€64.2K.